INKON Life Technology Co., Ltd.
盈康生命
300143
Shenzhen Stock Exchange
Company Profile
(1) Medical Services Yingkang Life, with its "strong specialists and strong generalists" model, provides comprehensive medical services focused on tumor treatment across the entire disease cycle. Its integrated "hospital + platform + ecosystem" approach has delivered significant results. As of the reporting date, the company operated and managed 10 hospitals and nursing homes, including top-tier institutions such as Sichuan Friendship Hospital and Suzhou Guangci Tumor Hospital. Several of its hospitals have achieved "5-star 3A" certification or been listed on relevant rankings, establishing a full-scenario medical service industry pattern that spans serious medical treatment, critical illness rehabilitation, and nursing elderly care. Hospitals: First, the company strengthened its specialties by focusing on tumor services. It enhanced its capabilities in the entire process of tumor prevention, diagnosis, treatment, and rehabilitation, established a full-scenario management system to address patient pain points, increased tumor-related revenue, and secured recognition of Friendship Hospital as a pilot unit. Second, it reinforced its technological capabilities by introducing new technologies, launching new projects, and adding new equipment, which enabled multiple innovations and "first-ever" surgical achievements at national and provincial levels. Third, it bolstered talent development through the "three-specializations" strategy and an entrepreneurship partner mechanism to boost the capabilities of medical professionals. Ecosystem: By leveraging its ecosystem advantages to enhance service capabilities, the company seized the opportunity of the silver economy and developed its nursing and elderly care business. It completed the entrustment of several related institutions, thereby closing the industrial loop and strengthening its capabilities. The company also clarified the positioning of regional medical centers, increased user stickiness through medical consortiums, and enhanced hospital brand influence by conducting charitable activities at schools, rural areas, communities, and nursing homes. Platform: Since 2021, it has laid out "AI + healthcare", gaining a first-mover advantage. It has built a full-scenario smart interaction engine for patients. Through cooperation with leading firms like United Imaging and iFlytek, it has improved AI technology and diagnostic services. Its hospitals have applied AI-enabled equipment and systems to raise diagnostic efficiency. (2) Medical Devices High R & D Investment and Innovation: R & D investment was stable, with a 39% CAGR over three years. By integrating resources and optimizing the R & D process, the company has achieved remarkable results. The application of AI technology in medical devices is gradually being implemented. Through industry-academia-research collaboration with prestigious universities and institutions, knowledge sharing and technological exchange are promoted, accelerating the transformation of R & D achievements. Rich Product System: The company has a diverse product portfolio covering four major scenarios - radiotherapy, life support, image enhancement, and chronic disease treatment. It provides comprehensive solutions for key tumor-related scenarios and equipment. Full-Scenario Digitalization Service Capability: The company focuses on the stability, safety, and digitalization of medical devices to build scenario-based service capabilities. Its subsidiary, Tongdayi, stands out. With its digital technology, it solves information silo problems and drives the digital transformation of the medical industry. Advanced Quality and Smart Manufacturing System: The company adheres to product quality standards, strictly implementing the ISO13485 standard and quality management regulations for medical device production. It continuously optimizes management processes and, leveraging Haier Group's top-notch lean manufacturing system, enhances production processes, supply chain capabilities, and production management to build an advanced smart manufacturing system for Yingkang Life's medical devices.
Full description
Focus on building a full - industry ecosystem platform for pre - treatment, diagnosis, treatment, and rehabilitation. The company recorded a revenue of RMB 155.92 million, representing a YoY increase of 6.01%, and a net profit attributable to shareholders of RMB 115.42 million, up by 14.92% YoY. This growth mainly stems from its medical services and medical devices businesses. 1.Medical Services: Oncology - Focused and AI - Enhanced (1) Oncology - Specialized Development: With a focus on oncology - centered full - cycle treatment, the business registered an oncology - related revenue of RMB 379.79 million, accounting for 31.9% of the total. Remarkable progress was made in cancer treatment, including Sichuan Friendship Hospital's recognition as a national cancer screening and management pilot and Guangci Hospital's ranking sixth in the 2024 list of top private oncology hospitals. (2) Differentiated Development of Specialized Disciplines: Guided by the "three - specialized" strategy, the company has innovated in various aspects to meet user - specific demands. It has introduced cutting - edge technologies to enhance diagnosis and treatment, and improved patient experience through hardware upgrades and innovative services. Its hospitals have also actively expanded commercial insurance payment channels. (3) AI + Healthcare - Driven New Ecosystem: As a medical group with unified AI deployment, the company has explored AI applications in healthcare, achieving remarkable progress in diagnosis, patient experience, and operations. It has completed the 1.0 and 2.0 stages of digitalization and entered the 3.0 stage of AI application, building a three - tier AI + healthcare layout to serve patients and medical staff comprehensively. 2.Medical Devices: Promoting High - End Domestic Products and Entering Overseas Markets (1) High - End Development: The medical devices business has achieved high - quality growth through product and channel upgrades. In high - end product upgrades, the company has launched products comparable to international ones with AI - enabled technological innovation. Strict quality control measures have been implemented, with high product acceptance rates. In high - end channel upgrades, the company has strengthened its presence in top - tier hospitals, expanded its direct sales network, and enhanced cooperation with industrial partners. (2) International Development: The company has entered several new overseas markets, such as in South America. Through localized registration and academic marketing, it provides overseas customers with all - around value - added services, achieving a 22% YoY growth in overseas revenue.